
|Podcasts|May 18, 2021
OncView Podcast: Genomic Testing in HR+ Breast Cancer to Guide Therapy in the Extended Adjuvant Setting
Author(s)Kristie L. Kahl
In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD about the current role of genomic testing in HR-positive breast cancer.
Advertisement
As part of its OncView video series, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD, University of Illinois College of Medicine, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.
In the video series, Gadi discussed the following:
Adjuvant Vs Extended Adjuvant Therapy in HR+ Breast Cancer Predictive and Prognostic Factors in HR+ Breast Cancer Role of Genomic Testing in HR+ Breast Cancer NCCN Guideline Updates for the Use of Genomic Assays in HR+ Breast Cancer Identifying Patients for Extended Adjuvant Therapy With the Breast Cancer Index in HR+ Breast Cancer Improving the Management of HR+ Breast Cancer: Next Steps
To watch more videos in CancerNetwork’s OncView series, visit
Advertisement
Related Content
Advertisement

ByKomal L. Jhaveri,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Phillippe Aftimos,Cristina Saura,Joyce O’Shaughnessy, MD,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Giuseppe Curigliano,Junichiro Watanabe,Elgene Lim, MBBS, FRACP, PhD,Juan Huang,Qingyuan Zhang,Antonio Llombart-Cussac,Chiun-Sheng Huang,Bhardwaj Desai,Xuejing Aimee Wang,Shanshan Cao,Francois Clement Bidard




Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Data Readouts to Watch at the 2026 ASCO Annual Meeting
2
Osteosarcoma Drug Earns Rare Pediatric Disease, Orphan Drug Designations
3
Alpha DaRT Elicits 100% Local Disease Control in Pancreatic Cancer
4
ArteraAI Pathology Test Launches for Personalizing Prostate Cancer Therapy
5


















































